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Dominant mutations in GARS, encoding the ubiquitous enzyme glycyl-tRNA synthetase
(GlyRS), cause peripheral nerve degeneration and Charcot-Marie-Tooth disease type 2D
(CMT2D). This genetic disorder exemplifies a recurring paradigm in neurodegeneration,
in which mutations in essential genes cause selective degeneration of the nervous
system. Recent evidence suggests that the mechanism underlying CMT2D involves
extracellular neomorphic binding of mutant GlyRS to neuronally-expressed proteins.
Consistent with this, our previous studies indicate a non-cell autonomous mechanism,
whereby mutant GlyRS is secreted and interacts with the neuromuscular junction
(NMJ). In this Drosophila model for CMT2D, we have previously shown that mutant
gars expression decreases viability and larval motor function, and causes a concurrent
build-up of mutant GlyRS at the larval neuromuscular presynapse. Here, we report
additional phenotypes that closely mimic the axonal branching defects of Drosophila
plexin transmembrane receptor mutants, implying interference of plexin signaling in gars
mutants. Individual dosage reduction of two Drosophila Plexins, plexin A (plexA) and B
(plexB) enhances and represses the viability and larval motor defects caused by mutant
GlyRS, respectively. However, we find plexB levels, but not plexA levels, modify mutant
GlyRS association with the presynaptic membrane. Furthermore, increasing availability
of the plexB ligand, Semaphorin-2a (Sema2a), alleviates the pathology and the build-up
of mutant GlyRS, suggesting competition for plexB binding may be occurring between
these two ligands. This toxic gain-of-function and subversion of neurodevelopmental
processes indicate that signaling pathways governing axonal guidance could be integral
to neuropathology and may underlie the non-cell autonomous CMT2D mechanism.
Keywords: axonal guidance, aminoacyl-tRNA synthetase (ARS), Charcot-Marie-Tooth disease type 2D (CMT2D),
distal spinal muscular atrophy type V (dSMA-V), GARS, glycyl-tRNA synthetase, neuromuscular disease,
neurodevelopment
INTRODUCTION
Dominant mutations in the glycyl-tRNA synthetase (GlyRS) gene, GARS, cause Charcot-
Marie-Tooth disease type 2D (CMT2D; Antonellis et al., 2003). CMT is a broad group of
genetically heterogeneous peripheral neuropathies that present with progressive motor and sensory
degeneration. Type 1/Demyelinating CMT is typified by demyelination leading to reduced nerve
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conduction velocities (NCVs), Type 2/Axonal CMTs display
axonal loss with relatively normal NCVs, while intermediate
forms share clinical features of the two. GARS is one of
several aminoacyl-tRNA synthetase (ARS) genes linked to CMT
(Jordanova et al., 2006; Latour et al., 2010; McLaughlin et al.,
2010; Gonzalez et al., 2013; Vester et al., 2013). In total,
there are 37 human ARS proteins, which catalyze the covalent
linkage of specific amino acids to their partner transfer RNAs
(tRNAs; Pang et al., 2014). As GlyRS, and ultimately glycine
aminoacylation, is essential in almost all cell types (Antonellis
et al., 2003; Alexandrova et al., 2015), the neuronal specificity
of the disease is puzzling. A number of potential mechanisms
have been hypothesized (Motley et al., 2010; Niehues et al., 2015;
Storkebaum, 2016), although the exact pathological processes
remain unknown. Notwithstanding, cellular and mouse studies
suggest that CMT2D is caused by a gain-of-function in mutant
GlyRS rather than GARS haploinsufficiency, or loss of canonical
glycine aminoacylation or a secondary non-canonical function
(Seburn et al., 2006; Nangle et al., 2007; Xie et al., 2007; Achilli
et al., 2009; Motley et al., 2011).
Numerous mutations in GARS have been shown to cause a
similar conformational change to GlyRS, leading to a structure
that can bind to erroneous targets (He et al., 2011). Given
that GlyRS is secreted (Park et al., 2012; Grice et al., 2015b;
He et al., 2015), these mis-interactions are not necessarily
restricted to within cells. Indeed, recent studies have shown
that neomorphic regions in mutant GlyRS facilitate aberrant,
extracellular interactions with Neuropilin 1 (Nrp1; He et al.,
2015) and the tropomyosin receptor kinase (Trk) receptors
(Sleigh et al., 2017a). In conjunction with plexins and other
co-receptors, Nrp1 binds to extracellular signaling proteins such
as the semaphorins and vascular endothelial growth factor
(VEGF), and is part of cell-cell communication that governs
the processes guiding the development of both the nervous
and vascular systems (Neufeld et al., 2002; Supplementary
Figure S1). Similarly, the Trk receptors bind to target-
secreted, extracellular growth factors, and play a key role
in the development, differentiation and survival of sensory
nerves (Lindsay, 1996). The interaction of mutant GlyRS with
Nrp1 selectively antagonizes VEGF signaling (He et al., 2015),
preferentially impacting the nervous, but not the vasculature,
system (Sleigh et al., 2017b). Neomorphic interactions between
mutant GlyRS and anomalous targets are thus likely to play an
important role in the manifestation of CMT2D.
CMT2D patients generally present during adolescence with
progressive muscle weakness in the distal limbs due to axon loss,
while NCVs and myelination remain unperturbed (Antonellis
et al., 2003; Sivakumar et al., 2005). In addition to axonal
degeneration (Seburn et al., 2006; Achilli et al., 2009), CMT2D
mice display denervation (Seburn et al., 2006; Achilli et al.,
2009; Motley et al., 2011; Sleigh et al., 2014b) and impaired
neurotransmission (Spaulding et al., 2016) at the neuromuscular
junction (NMJ), which is preceded by defective synaptic
development (Sleigh et al., 2014b).
In Drosophila, we have shown that mutant GlyRS is secreted
by muscle and interacts with the NMJ (Grice et al., 2015b).
This gain-of-function, non-cell autonomous mechanism causes
both degenerative and developmental abnormalities in the
Drosophila nervous system. The mechanisms underlying these
defects remain unknown, but interactions with neuropilin-
plexin-semaphorin signaling is an attractive possibility for a
number of reasons. First, in vertebrates, mutant GlyRS binds
to and interferes with the canonical function of the plexin-
interacting protein Nrp1. Second, plexin-semaphorin signaling
controls processes perturbed in a number of CMT2D animal
models (outlined above) including neurotransmission (Carrillo
et al., 2010; Orr et al., 2017), synaptic establishment and
maturation (Hu et al., 2001; Ayoob et al., 2006; Berke and
Keshishian, 2011), and active zone protein dynamics (Orr et al.,
2017). Finally, in this report, characterization of flies expressing
mutant gars identified phenotypes that mimic those associated
with perturbed plexin-semaphorin signaling. Though no direct
Drosophila ortholog of Nrp1 has been identified, the fly has
two plexin genes, plexin A (plexA; Winberg et al., 1998) and
plexin B (plexB; Hu et al., 2001), which independently bind to
different semaphorin classes and are critical to the process of
axon guidance (Schuster et al., 1996; Hu et al., 2001), retrograde
signaling at the synapse, and synaptic plasticity (Orr et al., 2017).
As mentioned above, we now report that mutant GlyRS
expression mimics the axonal branching defects generated
by loss-of-function mutations in the two fly plexins, plexA
and plexB. Moreover, we show that dosage reduction of
plexA and plexB enhances and represses the viability and
motor function defects caused by mutant gars expression,
respectively. plexA and plexB dosage changes also modify
adherent axonal protein localization, whilst reduction of plexB
ameliorates the toxic build-up of GlyRS at the synapse. The
centrality of PlexB signaling to mutant GlyRS toxicity is further
highlighted by the observation that overexpression of the PlexB
ligand, Semaphorin-2a (Sema2a), suppresses mutant GlyRS
synaptic binding and associated neuropathology. This reveals
an important role for plexins in mutant GlyRS pathology and




Reagents were obtained from Sigma-Aldrich unless otherwise
stated. All Drosophila stocks were cultured on standard
molasses/maize meal and agar medium in plastic vials or
bottles at 20 or 25◦C. The garsP234KY and garswt stocks have
been previously described (Grice et al., 2015b). 1032-GAL4,
elav-GAL4, MHC-GAL4, the plexA loss-of-function mutant
plexAMB09499, UAS-plexA and the plexB loss-of-function mutant
plexBKG00878, were obtained from the Bloomington Drosophila
Stock Center at Indiana University, and Alex Kolodkin
generously shared the UAS-Sema-1a, UAS-Sema-2a-TM-GFP,
and UAS-plexB-myc lines.
Drosophila Viability and Behavioral Assays
Adult viability assays were conducted by crossing GAL4 driver
stocks to lines harboring gars overexpression or to w1118 for
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controls. Embryos were then counted, lined on apple juice plates
with yeast, and larval development noted. Fresh yeast was added
daily. Two days post-eclosion the number of surviving adult
flies was counted for each genotype. Hundred flies per genotype
were scored over three independent experiments. Measurement
of motor function involved placing individual age-matched third
instar larvae at the center of a 0.7% (w/v) agar plate and counting
the forward body wall contractions exhibited in 2 min. Twenty
flies per genotype were scored.
Drosophila Larval NMJ Analysis
Larvae were reared, dissected and processed as previously
described with analysis of hemisegment A2 (Schuster et al.,
1996; Grice et al., 2015a,b), and at least 23 NMJs per genotype
per stage were scored. Ectopic branch contact analysis was
performed using L3 larval hemisegments A1 to A3, and
14 flies per genotype were scored. For axonal bruchpilot
(Brp) localization studies, the transverse nerve (TN) section
bypassing muscle 6 and 7 in hemisegments A2 and A3 was
used. For immunohistochemistry, anti-discs large (DLG, DSHB),
anti-HRP (Jackson), anti-Bruchpilot (DSHB) and anti-HA (Santa
Cruz) were all used at 1/100 in combination with secondary
antibodies, AlexaFluor 488 goat anti-rabbit and AlexaFluor
633 goat anti-mouse (Invitrogen) at 1/1000. Z-stacks were
taken using a Leica SP5 laser confocal microscope and analysis
performed using ImageJ and Photoshop (Adobe).
Quantitative RT-PCR (qPCR)
RNA was extracted from dissected L3 larval ventral nerve cords
using an RNeasy Mini Kit (QIAGEN), as per the manufacturer’s
instructions, and reverse transcribed as published previously
(Sleigh et al., 2014a). cDNA was diluted in water (1/10) before
mRNA levels were assessed by qPCR in 20 µl reactions using
SYBR Green (Applied Biosystems) and a StepOnePlus real-time
PCR machine (Applied Biosystems). Relative gene expression
was assessed as previously described (Lee et al., 2008; Sleigh
et al., 2014a). Primer sequences were as follows: plexA forward
5′-GCT CGT CGT TGA CAA AAT TCG-3′ and reverse 5′-TAA
ATG CGA CCC AGA TTG GTG C-3; plexB forward 5′-GCG
TTT TCA TCG TTA GCA GC-3′and reverse 5′-CAT TCG ACA
AGG AGC CTG C-3′. Three technical replicates per reaction
were performed, with each of three biological replicates, and
expression was normalized to rp42.
Statistical Analysis
When normally distributed, datasets were statistically analyzed
using either an unpaired t-test with Welch’s correction or
a one-way analysis of variance with Bonferroni’s multiple
comparison test. If the data did not pass normality testing,
the non-parametric Mann–Whitney U test or Kruskal–Wallis
test with Dunn’s multiple comparison test was used. Linear
regression analyses were performed to determine the
correlation between synaptic accumulation of mutant GlyRS
and neuropathological features of the CMT2D model. GraphPad




We use a Drosophila larval model for CMT2D (Grice et al.,
2015b), and concentrate on neuronal phenotypes in the
neuromuscular system caused by the mutant gars expression.
Both developmental and degenerative defects have been observed
in Drosophila CMT2D models (Chihara et al., 2007; Ermanoska
et al., 2014; Grice et al., 2015b; Niehues et al., 2015); however,
the causative mechanisms for many of these phenotypes
have not been identified. We have previously shown that
expression of mutant GlyRS in flies leads to motor deficits
and progressive NMJ denervation, mirroring CMT2D mice
(Sleigh et al., 2014b, 2017a; Spaulding et al., 2016), as well as
presynaptic accumulation of mutant GlyRS (Grice et al., 2015b).
In addition, we find that the neuronal toxicity is, at least in
part, non-cell autonomous (Grice et al., 2015b). Furthermore,
defects in synaptic establishment, maturation, function and
maintenance have been observed in invertebrate (Grice et al.,
2015b) and vertebrate Gars neuropathy models (Sleigh et al.,
2014b; Spaulding et al., 2016).
We now report a novel CMT2D phenotype of defective
synaptic wiring in the Drosophila neuromuscular system. The
Drosophila larval abdominal ventrolateral muscles 6 and 7 are
innervated in a stereotyped manner by defasciculated segmental
nerve d (SNd; Figures 1A,B). Other proximal nerves, such as
the TN and SNb, normally bypass these muscles. In wild-type
flies, SNb innervates the adjacent muscle 12, while the TN
entirely circumvents muscles 6, 7, 12 and 13. When a mutant
form of GlyRS is ubiquitously expressed using the GAL4-UAS
system (1032-GAL4 driver), ectopic synaptic contacts from
both the TN (Figures 1B,C; Supplementary Figures S2C,D)
and SNb (Supplementary Figure S2B) are often observed on
muscles 6 and 7 in garsP234KY flies. Consistent with the
non-cell autonomous disease mechanism we have previously
identified (Grice et al., 2015b), this occurs when garsP234KY
is expressed from muscle (MHC-GAL4; Figure 1D), but not
neurons (elav-GAL4), nor when wild-type gars is ubiquitously
expressed using the same driver (Figure 1E). This indicates
that mutant GlyRS disrupts normal axonal guidance, and
that this possibly occurs through cell-to-cell signaling rather
than disturbance of inherent neuronal pathways. We did
not see comparable defects in a model of spinal muscular
atrophy (SMA; Smnx7/Smnx7), suggesting that these defects
are not general to all Drosophila models of motor neuron
degeneration.
Heterozygous plexA and plexB Mutations
Enhance garsP234KY Axonal Branching
Defects
A recent study has shown that mutated GlyRS binds to the
membrane-bound protein Nrp1 (He et al., 2015), which acts as a
co-receptor with mammalian Plexin A for semaphorin signaling
(Tran et al., 2007). Whilst there is no direct Nrp1 ortholog, the
fly has two plexin orthologs, plexA (Winberg et al., 1998) and
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FIGURE 1 | garsP234KY expression phenocopies plexin mutants and subverts plexin-mediated axonal branching. (A) Schematic of the larval ventral body wall
muscles in one hemisegment, showing the transverse nerve (TN), and branches of segmental nerves b (SNb) and d (SNd). The ectopic synaptic contacts often
observed on muscles 6 and 7 in garsP234KY flies are shown in red. (B) In wild-type flies, SNb innervates muscle 12, while the TN entirely bypasses muscles 6, 7, 12
and 13. (C,D) Ectopic axons (arrows) and synaptic contacts can be observed from the SNb and the TN when garsP234KY is expressed ubiquitously (C) or in muscle
(D), phenocopying loss-of-function plexB homozygotes (Carrillo et al., 2010). (E) Ubiquitous (1032-GAL4) and muscle (MHC-GAL4) garsP234KY expression, but not
mutant neuronal (elav-GAL4) or ubiquitous wild-type gars expression, lead to an increased number of ectopic contacts in L3 larvae. This is not seen in a model of
spinal muscular atrophy (smnx7/smnx7), a second, unrelated neuromuscular condition. Ectopic branches are scored from both the TN and the SNb nerve.
(F) Expressing garsP234KY with a ubiquitous driver in either a plexA or plexB heterozygous knockout background significantly enhances the branching defects from
the TN nerve. ∗P < 0.05, ∗∗P < 0.01, Dunn’s multiple comparison test. N.b., garsP234KY is not expressed in the following flies: control, Smnx7/Smnx7, plexA/+,
plexB/+, Smnx7/Smnx7; plexA/+ and Smnx7/Smnx7; plexB/+ (E,F). Scale bars = 10 µm. For all experiments, n > 16 larvae per genotype. Error bars
represent ± standard error of the mean (SEM). See also Supplementary Figure S2.
plexB (Hu et al., 2001), which independently bind to different
semaphorin classes. Due to their role in axonal attraction and
repulsion, knock-down of the Drosophila plexins drives diverse
axon guidance defects in the embryo, while total loss of the
plexin proteins leads to fly lethality (Winberg et al., 1998; Hu
et al., 2001; Ayoob et al., 2006). Intriguingly, the CMT2D model
presented here (i.e., mutant gars-expressing flies), phenocopies
the wiring defects of both plexA and plexB loss-of-function
mutants (Figures 1A–E).We therefore looked to see if alterations
in plexin levels modify the axonal guidance defects observed
when garsP234KY is expressed. To reduce plexin levels in mutant
gars flies, we crossed heterozygous loss-of-function mutants
of both plexA (plexAMB09499) and plexB (plexBKG00878) to flies
ubiquitously expressing garsP234KY , and re-scored the number of
ectopic contacts occurring between the TN and muscles 6 and
7. We found that heterozygous reduction of both plexA and
plexB enhanced the ectopic branching defects observed inmutant
GlyRS flies (Figure 1F), suggesting that garsP234KY expression
interferes with plexin-mediated axonal guidance. Again, we did
not see any modifications in the SMA model (Smnx7/Smnx7),
suggesting that the enhancements are specific to the CMT2D
model.
Differential Effects of PlexA and B on
garsP234KY Lethality and Motor Dysfunction
Mutant GlyRS causes both larval and adult phenotypes in the
fly (Ermanoska et al., 2014; Grice et al., 2015b; Niehues et al.,
2015); however, the axonal branching defects in both plexin
and garsP234KY mutants are likely to originate during embryonic
development and larval growth. We therefore assessed plexA
and plexB expression in larval and adult nervous systems using
quantitative RT-PCR (qPCR). The RNA of both genes was
detected in the larval central nervous system, and the adult brain
and ventral nerve cord (Supplementary Figure S3), suggesting
that both plexins function throughout life.
We next looked to see how modifying plexin levels impacts
the adult lethality and larval motor defects when garsP234KY
is expressed ubiquitously using 1032-GAL4 (going forward
referred to as garsP234KY flies). Ubiquitous expression of
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FIGURE 2 | Plexin mutants modify glycyl-tRNA synthetase (GlyRS)P234KY -associated viability and motor defects. (A) Expressing garsP234KY with a ubiquitous driver
(1032-GAL4) in a plexB heterozygous loss-of-function background significantly alleviates adult viability defects, while plexB overexpression reciprocally causes full
lethality. Contrastingly, garsP234KY expression in a plexA loss-of-function background leads to a decrease in viability, while its overexpression has no effect.
(B) garsP234KY expression in plexB heterozygous larvae partially rescues muscle contractions, whilst garsP234KY expression in a plexA background enhanced the
motor defect. plexA overexpression partially restores movement, while plexB overexpression enhances the motor defect. The larval motor defects are thus analogous
to the adult viability defects in (A). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 Dunn’s multiple comparison test. N.b., garsP234KY is not expressed in the plexA/+ and
plexB/+, control flies (third and fourth bars from the y-axes, respectively). For viability assays, n > 100 flies per genotype; for contraction assays, n > 20 larvae per
genotype. Error bars represent ± SEM.
garsP234KY significantly reduced adult viability, with only 7%
surviving to the adult stage. We found plexA and plexB reduction
had opposing effects on the adult viability defect of garsP234KY
flies: reduction of plexA compounded the reduced viability (1%
survival), whilst diminishing plexB levels significantly improved
survival (21% survival). Alternatively, increasing plexA had
no significant effect, while plexB overexpression reciprocally
exacerbated the garsP234KY viability phenotype, with no flies
(0%) making it to the late pupal stage (Figure 2A). These results
were corroborated by larval motor function testing (Figure 2B).
When mutant gars is expressed, larval muscular contractions
(a surrogate for larval motor function) decrease in number
(∼20 contractions/min are observed in the mutant compared to
∼39 mean in controls). The defects in muscle function of mutant
gars-expressing flies were worsened in plexA heterozygotes
(∼10 contractions/min) and marginally improved in plexA
overexpressors (∼27 contractions/min). PlexB reduction
improved contraction frequency (∼28 contractions/min) and
plexB overexpression exacerbated it (∼4 contractions/min). It
should be noted that reduced PlexB levels enhanced the wiring
defect (Figure 1F) but ameliorated the viability and motor
phenotypes (Figure 2), suggesting that the neurodevelopmental
branching defects do not contribute to the reduced viability of
garsP234KY flies and that mutant pathology is not due to loss of
PlexB function. Due to the severe nature of the adult phenotypes,
and given that the garsP234KY flies surviving to adulthood die
soon after eclosing, we did not perform movement assays in
adults.
Plexin Levels Differentially Modify Axonal
Accumulation of the Active Zone Protein
Bruchpilot in Mutant GlyRS Flies
We next determined how altered plexin levels modify additional
key phenotypes of the Drosophila CMT2D model. First,
we looked at the previously described axonal accumulation
of the active zone-associated protein Brp (Figures 3A–D,
Supplementary Figure S4; Grice et al., 2015b), which is a
potential early indicator of neuropathology (Johnson et al.,
2009) that may be caused by axonal transport defects (Goldstein
et al., 2008). Both ubiquitous and muscle expression of mutant
GlyRS lead to Brp protein accumulation in the axons of
the peripheral nervous system. This appears to be driven
via a non-cell autonomous mechanism as Brp build-up is
not seen when mutant gars is expressed in neurons (Grice
et al., 2015b). Quantification of the number of Brp-positive
foci in the region of the TN adjacent to muscle 6 and
7 was performed in GlyRS mutant flies crossed with either
the plexin heterozygous loss-of-function mutants, or the plexin
overexpressors. In wild-type and control flies, Brp foci are
limited, but can be observed in some axons (Figure 3A;
∼3 axonal foci per section in controls). This number dramatically
increases when mutant gars is expressed (∼20 axonal foci
per section). Concordant with the differential effects on viability
(Figure 2), a reduction of plexB levels reduced Brp accumulation
(∼12 axonal foci per section), while plexB overexpression
enhanced Brp accumulation (∼36 axonal foci per section;
Figure 3D). Conversely, Plexin A overexpression reduced the
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FIGURE 3 | plexA and plexB dosage changes modify GlyRSP234KY -associated axonal defects and mutant GlyRS accumulation at the neuromuscular junction (NMJ).
(A–C) Digitally inverted images of the TN showing increased axonal bruchpilot (Brp) compared to control (A) upon ubiquitous (B) and muscle-specific (C) garsP234KY
expression. (D) The build-up of Brp in axons of the TN caused by ubiquitous GlyRSP234KY expression is modulated by alterations in PlexA or PlexB levels. Greater
Brp accumulation is observed upon PlexA reduction and PlexB overexpression, whereas an increase in PlexA and a decrease in PlexB ameliorate Brp build-up. N.b.,
garsP234KY is not expressed in the plexA/+ and plexB/+ control flies (third and fourth bars from the y-axis, respectively). (E) An example of GlyRSP234KY (HA staining)
accumulation at the presynapse when ubiquitously expressed. (F) GlyRSP234KY accumulates at the neuronal membrane, and correlates with PlexB, but not PlexA,
levels, i.e., increased and decreased abundance of PlexB causes increased and decreased mutant GlyRS build-up, respectively. (G) When expressed with a
ubiquitous driver, PlexB localizes at the NMJ with the neuronal marker HRP. (H) PlexB and GlyRSP234KY localize to the NMJ when co-expressed using a ubiquitous
driver. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 Dunn’s/Bonferroni’s multiple comparison test. #: displayed a significant increase when compared to the mutant GlyRS
background alone (Mann-Whitney U test, P = 0.03). All experiments are performed expressing garsP234KY with a ubiquitous driver (1032-GAL4). Scale bar = 10 µm.
For all experiments, n > 20 larvae per genotype. Error bars represent ± SEM. See also Supplementary Figure S4.
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FIGURE 4 | Overexpression of the Plexin B ligand Semaphorin-2a (Sema2a) suppresses mutant GlyRS-mediated neuropathology. (A) Expressing Sema2a, but not
Sema1a, in garsP234KY flies (using the muscle driver MHC-GAL4) significantly alleviates mutant motor defects (compare garsP234KY with garsP234KY , Sema2a OE). In
the plexB heterozygous loss-of-function background, this amelioration is further improved (compare garsP234KY , Sema2a OE with garsP234KY , Sema2a OE; plexB/+).
In contrast, reduction of plexA levels abrogates the amelioration caused by Sema2a overexpression in garsP234KY flies (compare garsP234KY , Sema2a OE; plexA/+
with garsP234KY and garsP234KY , Sema2a OE). (B,C) Consistent phenotype correlations were seen for both axonal Brp build-up (B) and synaptic accumulation of
GlyRSP234KY (C). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 Dunn’s/Bonferroni’s multiple comparison test. N.b., garsP234KY is not expressed in the Sema1a OE and
Sema2a OE control flies (third and seventh bars from the y-axes, respectively). All experiments are performed expressing garsP234KY with a ubiquitous driver
(1032-GAL4). For all experiments, n > 20 larvae per genotype. Error bars represent ± SEM. See also Supplementary Figure S3.
accumulation of axonal Brp in the GlyRS mutant flies, while
plexA reduction enhanced the build-up.
Plexin B Levels but Not Plexin A Modify
Mutant GlyRS Accumulation at
Neuromuscular Synapses
The neomorphic binding of mutant GlyRS to neuronal
membrane proteins has been shown to be a potential mechanism
for the toxic gain-of-function associated with CMT2D (He
et al., 2015; Sleigh et al., 2017a). We therefore wanted to
understand if alterations in plexin levels affect the accumulation
of mutant GlyRS at the Drosophila neuromuscular synapse.
We have previously reported that mutant but not wild-type
GlyRS accumulates at the presynaptic NMJ in third instar larvae
(Grice et al., 2015b; Figure 3E). This build-up coincided with
NMJ defects described in the same report. We found that
reducing plexB decreased the intensity of mutant GlyRS staining
at the presynapse (51% decrease, Figure 3F). There was a trend
for plexB overexpression to increase the build-up of mutant
GlyRS at the presynapse, which was significantly greater when
compared is isolation to the mutant GlyRS flies (35% increase
Mann-Whitney U test, P = 0.03), suggestive of a reciprocal
pattern associated with down- and up-regulation of Plexin B.
No significant alterations were observed with plexA reduction
or overexpression, suggesting that the synaptic accumulation
of mutant GlyRS is observably modified by Plexin B alone.
The expression patterns of plexins, are not well understood,
due in part to a lack of reliable antibodies. We therefore
overexpressed myc-tagged Plexin B and found that it localized
to the presynaptic neuron (Figure 3G), where it co-stained
with the mutant GlyRS protein (Figure 3H). The dependence
of presynaptic GlyRS accumulation on Plexin B parallels the
mammalian association of mutated GlyRS with Nrp1 (He et al.,
2015).
Overexpression of Sema2a, the PlexB
Ligand, Suppresses Mutant GlyRS-linked
Neuropathology
If presynaptic accumulation of mutant GlyRS and the associated
neuromuscular defects are dependent on the aberrant binding of
mutant GlyRS to plexins, we might expect that overexpression
of the natural plexin ligands could supress the disease
phenotypes through competitive binding. PlexA is the receptor
for transmembrane semaphorin-1a (Sema1a), while PlexB
is the main receptor for the secreted semaphorin Sema2a
(Winberg et al., 1998; Ayoob et al., 2006). To mimic the
non-cell autonomous effect, we expressed both Sema1a and
Sema2a using a muscle-specific driver (Figure 4). Sema1a
overexpression conferred no alteration in GlyRSP234KY fly motor
function (Figure 3A), axonal Brp accumulation (Figure 4B), or
synaptic GlyRS build-up (Figure 4C). In addition, no further
modifications were observed when Sema1a was overexpressed
in the mutant garsP234KY ; plexA/+ and mutant garsP234KY ;
plexB/+ backgrounds (Figure 4). This suggests that the
mutant GlyRS pathology is not dependent on Sema1a-
PlexA.
In stark contrast, Sema2a overexpression ameliorated
the GlyRSP234KY muscle contraction defect (Figure 4A,
Supplementary Figure S4), as well as decreasing axonal Brp foci
(Figure 4B) and aberrant synaptic GlyRS build-up (Figure 4C).
Moreover, additive improvements in the three phenotypes
occurred when mutant GlyRS and Sema2a were expressed in
the plexB heterozygous mutant background (Figures 4A–C).
Surprisingly, Sema2A overexpression eliminated the phenotypic
enhancement in severity conferred by plexA heterozygosity.
However, as a possible compensatory mechanism, plexB
expression is modestly increased in plexA heterozygous flies
(Supplementary Figure S3). It is therefore possible that plexA
modification of the mutant GlyRS phenotype, and therefore
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FIGURE 5 | Synaptic accumulation of mutant GlyRS correlates with neuropathology. (A,B) Linear regression analyses identifying correlations between synaptic
mutant GlyRS build-up with both muscular contractions (A, r2 = 0.727; P = 0.0015) and axonal Brp build-up (B, r2 = 0.945; P < 0.001).
the amelioration caused by Sema2A overexpression, is at least
partially mediated through increased PlexB levels.
DISCUSSION
We have shown that key pathologies in a Drosophila model of
CMT2D can be modified by alterations in plexin-semaphorin
signaling. Drosophila possess two plexins, PlexA and PlexB,
which differentially bind semaphorins to provide cell-cell
communication that drives axon repulsive and attractive cues.
We show that mutant GlyRS expression leads to ectopic axonal
branches in the peripheral nervous system, and this phenotype
is modifiable by altering the levels of the Drosophila plexins,
PlexA and PlexB. We then show that heterozygous reduction
of PlexB ameliorates the lethality and neuropathology caused
by garsP234KY expression, while PlexA reduction exacerbates the
same phenotypes. In addition, PlexB, but not PlexA, appears
to be important for the association of mutant GlyRS with the
neuromuscular synaptic membrane. Furthermore, we found that
increasing expression of the secreted PlexB ligand, Sema2a, but
not the PlexA ligand, Sema1a, can also supress the mutant
GlyRS binding and motor defects. Finally, we show that the
fluctuations in mutant GlyRS build-up at the NMJ, caused
by manipulation of plexin-semaphorin components, correlates
significantly with the pathological features identified in the
CMT2D model (Figures 5A,B). Taken together, these data
highlight the importance of plexin-semaphorin signaling in the
regulation of mutant GlyRS toxicity and accumulation, and the
role of the PlexB-Sema2a on mutant GlyRS synaptic build-up.
In both invertebrates and vertebrates, plexin signaling drives
the attractive and repulsive signals required for high-fidelity
nerve-nerve, nerve-muscle and nerve-glia interactions (Winberg
et al., 1998; Hu et al., 2001; Ayoob et al., 2006; Berke and
Keshishian, 2011; Roh et al., 2016; Syed et al., 2016). Although
CMT2D is thought to be primarily degenerative in nature,
neurodevelopment and maturation defects are observed in
invertebrate (Grice et al., 2015b) and vertebrate (Sleigh et al.,
2014b, 2017a) models, with motor neuron migration (He et al.,
2015) and sensory neuron branching defects seen in mutant
mouse embryos (Sleigh et al., 2017a). It has not been established
how the neurodevelopmental defects arise and whether they
are a precursor to pathology, or an epiphenomenon. Our
data in Drosophila indicate that mutant GlyRS interferes
with the fidelity of axon guidance pathways that are partly
governed by both PlexA and PlexB signaling. As mutant
GlyRS expression both phenocopies and modifies the plexA
and plexB axonal branching defects, we suggest that the ectopic
branching phenotype arises from mutant GlyRS interaction
and interference with canonical plexin signaling. Importantly,
however, whilst we found opposing effects of PlexA and PlexB
on toxicity phenotypes and associated pathology, the same
neurodevelopment defects were exacerbated with reduction of
either plexin. Hence, the data suggest that axonal guidance
defects are de-coupled from the neurodegenerative pathology,
mirroring the developmental switching in sensory neuron
identity observed in Gars mice that appears to be independent
from the progressive peripheral nerve degeneration (Sleigh et al.,
2017a).
In this study, we use the larval NMJ to examine the interaction
between the plexin-semaphorin components and mutant GlyRS
toxicity. However, unravelling the complete contribution of
plexin-semaphorin signaling to CMT2D, in both the peripheral
and central nervous systems, is made difficult by the complexity
of the temporally and spatially diverse functions mediated
through both plexin types (Neufeld et al., 2011; Roh et al.,
2016). For example, Drosophila PlexA has been shown to drive
repulsive axon guidance cues in the embryo, whilst PlexB
can initiate either repulsive or attractive cell-cell interactions
depending on the cellular environment (Winberg et al., 1998;
Berke and Keshishian, 2011;Wu et al., 2011; Jeong et al., 2012). In
addition, the repulsive and attractive actions aremediated though
different ligands and interact with different downstream effectors
(Winberg et al., 1998; Hu et al., 2001; Ayoob et al., 2006; Bates and
Whitington, 2007; Berke and Keshishian, 2011; Cho et al., 2012;
Roh et al., 2016). Plexin A binds strongly to the Sema1 class of
semaphorins, while Plexin B binds to the Sema2 class (Winberg
et al., 1998; Ayoob et al., 2006; Bates and Whitington, 2007). The
plexin-semaphorin interactions occur in both competitive and
cooperative processes, and can involve both forward and reverse
signaling cascades. We show that overexpression of Sema2a in
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larval muscle suppresses the motor and neuronal phenotypes
observed when mutant GlyRS is expressed. In contrast, there
is no change in the phenotypic readouts when the class
1 semaphorin, Sema1A, is overexpressed. Accordingly, PlexB
reduction, unlike PlexA, was able to partly rescue the mutant
GlyRS lethality. We thus propose that PlexB is required for
the build-up of mutant GlyRS at the NMJ, and ultimately
the toxicity caused by expression of garsP234KY . Mutant GlyRS
could be competing with Sema2A binding at the larval NMJ,
and interfere with other membrane-bound or secreted factors
associated with different neuronal cell types, or at different
developmental time points. It is likely that the plexB heterozygote
fly did not produce a complete rescue of mutant GlyRS because
plexB is still expressed, albeit at a reduced level. Consistent with a
role for PlexB-mutant GlyRS binding in synaptic accumulation,
the overexpression of Sema2A, particularly in the reduced
plexB fly, led to further reduction in GlyRS build-up and an
additive improvement in disease phenotypes, presumably by
out-competing mutant GlyRS.
Within the cell, GlyRS charges glycine to its cognate tRNA;
however, in a non-canonical tumur-defense capacity, GlyRS also
binds to the extracellular receptor protein K-cadherin (Park
et al., 2012). Moreover, GlyRS functions in neddylation by
interacting with NEDD8 (Mo et al., 2016). A non-canonical
neuronal receptor protein has not yet been reported for wild-type
GlyRS, but mutant GlyRS has been shown to interact with
multiple anomalous targets (He et al., 2015; Sleigh et al., 2017a).
Our data suggest that Plexin B may either be an additional,
or fly-specific, aberrant target, or an indirect modifier of the
interactions that drive the association of mutant GlyRS with
the presynaptic membrane. In mice, mutated GlyRS erroneously
binds to Nrp1 and this interaction competes with the binding
of the endogenous ligand VEGF (He et al., 2015). The data we
present here are similar in that an anomalous interaction between
mutated GlyRS and PlexB competes with the endogenous
ligand, Sema2A. Indeed, VEGF treatment partially rescues
motor function of the CMT2D mice and Nrp1 heterozygosity
exacerbates it (He et al., 2015), while reduced expression of
VEGF in wild-type mice has been shown to contribute to motor
neuron degeneration (Oosthuyse et al., 2001). These findings
argue that in both fly andmouse, secretedmutant GlyRS interacts
with neuronally-expressed transmembrane proteins involved in
signaling. The downstream consequences of aberrant binding
remain to be elucidated; however, the amelioration of the
phenotype by reducing plexin B indicates that loss of Sema2A-
PlexB signaling is not the mechanism. Instead, the strong
correlation we observed between presynaptic mutant GlyRS
accumulation and neuromuscular dysfunction suggests that the
former is an important part of the pathogenic process (Figure 5).
We have suggested that Plexin B may either be an anomalous
target for mutant GlyRS, or an indirect modifier of the
interactions that drive the association of mutant GlyRS with
the presynaptic membrane. Our data also suggest that PlexA
may further modify the phenotypes indirectly through its
physiological antagonism of PlexB-driven processes. Interactions
of this nature have been noted previously; for example, PlexA
has been shown to partially rescue the PlexB mutant, but PlexB
did not reciprocally rescue PlexA mutants (Ayoob et al., 2006).
We have shown that the presence of the plexA heterozygous
mutation eliminates the mutant gars phenotype amelioration
conferred by Sema2A overexpression, suggesting that PlexA may
act independently on mutant GlyRS toxicity at the NMJ, and
downstream of PlexB. Beyond this, as multiple semophorin-
plexin interactions control nerve-nerve, nerve-muscle, and
nerve-glia communication (Ayoob et al., 2006; Bates and
Whitington, 2007; Yu et al., 2010; Syed et al., 2016), a range
of parallel mechanisms may cause defects that ultimately lead
to broader changes in the set-up and maintenance of neuronal
circuits and synapses of the animal. Moreover, additional
signaling pathways may drive parallel neuroprotective actions
within the nervous system, and therefore titre mutant GlyRS
binding and toxicity further.
In summary, we have shown that mutants GlyRS expression
interferes with plexin-mediated axonal branching, and that
the alteration of plexin-semaphorin signaling can modify
mutant GlyRS lethality, neuromuscular dysfunction, and
neuropathology. This toxic gain-of-function, and alteration
of neurodevelopmental pathways, highlights mechanisms
analogous to a mammalian model of the disease. Our findings
provide additional evidence of a new disease paradigm in
CMT2D, which provides further explanation for the selective
effect on the nervous system of mutations in a widely expressed
protein.
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